drugset
drugset / Trial / NCT04530227

Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLC

NCT04530227 ↗

Phase 2 Unknown 30 enrolled Tianjin Medical University Cancer Institute and Hospital
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the efficacy and safety of Camrelizumab plus chemotherapy in the treatment of adult participants with medically inoperable Stage I or IIA non-small cell lung cancer (NSCLC).

Timeline

Start
2020-09-25
Primary completion
2025-06-30
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Camrelizumab Monoclonal antibody 200 mg Intravenous
Background Nab-paclitaxel Small molecule — —
Background Pemetrexed Small molecule — —

Indications

non-small cell lung carcinoma